drugset
drugset / Trial / NCT04006054

Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury

NCT04006054 ↗

Phase 4 Unknown 82 enrolled Xiangya Hospital of Central South University
RandomizedParallel-groupSingle-blindPrevention

Summary

The aim of the study is to investigate whether dexmedetomidine could suppress catecholamine release into peripheral blood to prevent PSH attacks and to achieve neuroprotection.

Timeline

Start
2019-06-06
Primary completion
2021-06-30
Completion
2021-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.25 ug/kg —
Subject Dexmedetomidine Other / unclassified 0.75 ug/kg —
Comparator Midazolam Small molecule 0.25 ug/kg —
Comparator Midazolam Small molecule 0.75 ug/kg —

Indications

traumatic brain injury